Search results for "lower extremity revascularization"

showing 2 items of 2 documents

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Tri…

2021

Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 mg twice daily plus aspirin or matching placebo plus aspirin and followed …

Lower extremity revascularizationMalemedicine.medical_specialtylower extremity revascularization; major adverse cardiovascular events (MACE); major adverse limb events (MALE); peripheral artery disease; revascularization; rivaroxaban.lower extremity revascularizationArterial diseasemedicine.medical_treatmentDiseaseRevascularizationperipheral artery diseasePeripheral Arterial DiseaseRivaroxabanPhysiology (medical)Internal medicinemedicineHumansIn patientmajor adverse cardiovascular events (MACE)major adverse limb events (MALE)AgedRivaroxabanAspirinAspirinbusiness.industryMiddle AgedCardiologyrevascularizationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugSurgical revascularizationCirculation
researchProduct

Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial

2021

Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb and cardiovascular events. The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial demonstrated that rivaroxaban 2.5 mg twice daily reduced first events by 15%. The benefit of rivaroxaban on total (first and subsequent) events in this population is unknown.This study sought to evaluate the total burden of vascular events in patients with PAD after LER and the efficacy o…

MaleLower extremity revascularizationmedicine.medical_specialtyArterial diseasemedicine.medical_treatmentGlobal HealthRevascularizationPeripheral Arterial DiseaseRivaroxabanIschemiaInternal medicineHumansMedicineAgedRivaroxabanDose-Response Relationship Drugbusiness.industryIncidencefood and beveragesMiddle AgedPeripheralbody regionsTreatment OutcomeLower ExtremityArterial revascularizationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresFactor Xa Inhibitorsmedicine.drugJournal of the American College of Cardiology
researchProduct